| IPO Company Profile |
| SEC Filings | Peer IPO Companies |
| Anthra Pharmaceuticals, Inc. |
| 103 Carnegie Center, Suite 102, Princeton, NJ 08540 * (609) 514-1060 |
| The company is a specialized pharmaceutical company engaged in clinical development and obtaining regulatory approval of New Drug Applications and supplemental NDAs for a portfolio of its proprietary cancer drugs. |
| Manager | Tier | Phone |
| Allen & Company Incorporated | Lead Manager | (212) 339-2220 |
| Gruntal & Co | Co-manager | (212) 225-4334 |
| NASNTL: | ANTH | Wholesale: | SIC 5122 | |
| Type of Shares: | Common Shares | Filing Date: | 3/11/98 | |
| U.S. Shares Filed: | 2,400,000 | Filing Range: | $9.50 - $11.50 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $25,200,000 | |
| Primary Shares: | 2,400,000 | Expenses: | $500,000 | |
| Secondary Shares: | 0 | Post-IPO Shares: | 7,255,183 | |
| Employees: | 30 |
| Issuer's Law Firm: | Werbel & Carnelutti |
| Bank's Law Firm: | Morrison & Foerster |
| Registrar/Transfer Agent: | American Stock Transfer & Trust Co |
| Auditor: | KPMG Peat Marwick |
Dollar amounts in U.S. millions except for per share data | |||||
| 6 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 6/30/97 | 12/31/97 | 12/31/96 | 12/31/97 | ||
| Revenue: | $1.69 | $0.00 | $1.49 | Assets: | $8.89 |
| Net Income: | -$5.46 | -$4.90 | -$2.09 | Curr Assets: | $8.81 |
| EPS: | -$1.22 | Liabilities: | $20.36 | ||
| Prior EPS: | Curr Liab: | $1.06 | |||
| Cash Flow/Oper: | -$3.85 | -$4.49 | -$0.80 | Equity: | -$11.47 |
| Cash Flow/Fin: | $2.96 | $12.50 | $2.21 | Cash: | $8.79 |
| Cash Flow/Inv: | -$0.03 | -$0.01 | -$0.03 | Working Cap: | $7.74 |
| Competition |
| The pharmaceutical and biopharmaceutical industries are intensely competitive and competition from other pharmaceutical companies, biotechnology companies and other research and academic institutions is expected to increase. Many of these companies have substantially greater financial and other resources and research and development capabilities than the Company and have substantially greater experience in undertaking preclinical and clinical testing of products, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products. The Company is aware of other companies engaged in the development of anthracycline drugs as chemotherapeutic agents for various disease indications, including Pharmacia-Upjohn, Aronex, Sequus, Nexstar and Liposome Company, and a number of other companies and academic institutions are pursuing anthracycline drug research and are testing other anthracycline drugs. AD 32 may compete for certain uses with numerous other anthracycline drug products in development by others. In addition to these companies and institutions involved in the development of anthraycycline drugs, many other companies have developed products which may compete with AD 32. These companies include Zeneca, Bristol-Meyers Squibb, American Home Products, Smith-Kline Beecham, Eli Lilly, Roche, Schering Plough, Bioniche Inc., Mentor and Takeida-Abbott, all of which develop or commercialize anti-cancer therapies. With respect to the treatment of prostate cancer, Anthra also faces competition from companies developing radioactive seed implantation therapies, including Amersham/Mediphysics, North American Scientific, Theragenics, Imagyn Medical Technologies and International Isotopes. Furthermore, companies also exist that compete with Bonefos(R) by developing other bisphosphonates for the treatment of hypercalcemia and lytic bone disease. These companies include Proctor & Gamble, Sanofi, Novartis, Merck and MGI Pharmaceutical. There can be no assurance that the Company will develop products that are as effective as or achieve greater market acceptance than competitive products, or that the Company's competitors will not succeed in developing products and technologies either that are as effective as those being developed by the Company or that would render the Company's products and technologies less competitive or obsolete. |
| Business Plan |
| The company intends to implement a strategy based on the following key elements: (I) Concentrate on the Clinical and Commercial Development of Drugs With Demonstrated Activity in the Treatment of Specific Types of Cancer, (ii) Minimize the Time and Cost of Drug Development by the Prudent Selection of Product Candidates and Disease Indications and Through the Rigorous Design and Implementation of Clinical Testing Programs, (iii) Stage Development of Drug Candidates to Reduce Risks Inherent In Clinical Studies, (iv) Address the Significant and growing Demand of Large and Medium-Sized Pharmaceutical Companies for New Oncologic Products, (v) Form Strategic Collaborations With Selected Corporate Partners and (vi) Capitalize On the Significant Investment in Cancer Drug Discovery At Academic Institutions and Specialist R&D; Companies. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for progress payments for the acquisition of Bonefos, for development of products and for general corporate purposes including potential acquisitions and purchase of product inventory. |